Adaptimmune Therapeutics PLC Files Definitive Proxy Statement
| Field | Detail |
|---|---|
| Company | Adaptimmune Therapeutics PLC |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Adaptimmune proxy filed, shareholder vote coming May 29th on exec pay & board.
AI Summary
Adaptimmune Therapeutics PLC filed its definitive proxy statement on April 25, 2025, for its annual meeting on May 29, 2025. The company, focused on biological products, is seeking shareholder approval for matters related to its governance and operations. The filing details executive compensation, board nominations, and other corporate actions requiring shareholder votes.
Why It Matters
This filing provides shareholders with crucial information to make informed decisions on company leadership and strategic direction at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing, not indicating immediate financial distress or significant operational changes.
Key Numbers
- DEF 14A — Filing Type (Definitive Proxy Statement)
Key Players & Entities
- Adaptimmune Therapeutics PLC (company) — Registrant
- 0001104659-25-039042 (filing_id) — Accession Number
- 20250425 (date) — Filing Date
- 20250529 (date) — Meeting Date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with the information necessary to vote at the company's annual meeting, including details on director nominations, executive compensation, and other corporate matters.
When is the shareholder meeting for which this proxy statement is being filed?
The shareholder meeting is scheduled for May 29, 2025.
What is the company's primary business as indicated in the filing?
The company's primary business is in Biological Products (No Diagnostic Substances), SIC code 2836.
What is the filing date of this definitive proxy statement?
The definitive proxy statement was filed on April 25, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Adaptimmune Therapeutics PLC.